Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy

被引:16
|
作者
Wang, Yang [1 ]
Zhang, Hua-nian [1 ]
Niu, Chang-he [1 ]
Gao, Ping [1 ]
Chen, Yu-jun [1 ]
Peng, Jing [1 ]
Liu, Mao-chang [1 ]
Xu, Hue [1 ]
机构
[1] Wuhan Childrens Hosp, Dept Pharm, Wuhan 430016, Peoples R China
关键词
epilepsy; oxcarbazepine; 10-hydroxycarbazepine; population pharmacokinetics; drug interaction; CYP450; pediatric patients; Chinese children; ANTIEPILEPTIC DRUGS; LAMOTRIGINE; 10-HYDROXYCARBAZEPINE; VARIABILITY; AGE;
D O I
10.1038/aps.2014.76
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Aim: To develop a population pharmacokinetics model of oxcarbazepine in Chinese pediatric patients with epilepsy, and to study the interactions between oxcarbazepine and other antiepileptic drugs (AEDs). Methods: A total of 688 patients with epilepsy aged 2 months to 18 years were divided into model (n=573) and valid (n=115) groups. Serum concentrations of the main active metabolite of oxcarbazepine, 10-hydroxycarbazepine (MHD), were determined 0.5-48 h after the last dosage. A population pharmacokinetics (PPK) model was constructed using NLME software. This model was internally evaluated using Bootstrapping and goodness-of-fit plots inspection. The data of the valid group were used to calculate the mean prediction error (MPE), mean absolute prediction error (MAE), mean squared prediction error (MSE) and the 95% confidence intervals (95% Cl) to externally evaluate the model. Results: The population values of pharmacokinetic parameters estimated in the final model were as follows: K-a=0.83 h(-1), V-d=0.67 L/kg, and CL=0.035 L.kg(-1)h(-1). The enzyme-inducing AEDs (carbamazepine, phenytoin, phenobarbital) and newer generation AEDs (levetiracetam, lamotrigine, topiramate) increased the weight-normalized CL value of MHD by 17.4% and 10.5%, respectively, whereas the enzyme-inhibiting AED valproic acid decreased it by 3%. No significant association was found between the CL value of MHD and the other covariates. For the final model, the evaluation results (95% Cl) were MPE=0.01 (-0.07-0.10) mg/L, MAE=0.46 (0.40-0.51) mg/L, MSE=0.39 (0.27-0.51) (mg/L)(2). Conclusion: A PPK model of OXC in Chinese pediatric patients with epilepsy is established. The enzyme-inducing AEDs and some newer generation AEDs (lamotrigine, topiramate) could slightly increase the metabolism of MHD.
引用
收藏
页码:1342 / 1350
页数:9
相关论文
共 50 条
  • [21] Oxcarbazepine pharmacokinetics and tolerability in children with inadequately controlled epilepsy
    Rey, E
    Bulteau, C
    Motte, J
    Tran, A
    Sturm, Y
    D'Souza, J
    Markabi, S
    Pons, G
    Dulac, O
    JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (11): : 1290 - 1300
  • [22] Population Pharmacokinetics of Carbamazepine and Its Metabolite in Chinese Children with Epilepsy
    Wang, Li
    Liu, Ying
    THERAPEUTIC DRUG MONITORING, 2009, 31 (05) : 619 - 619
  • [23] Population pharmacokinetics of carbamazepine and its metabolite in Chinese children with epilepsy
    Wang, Li
    Liu, Ying
    THERAPEUTIC DRUG MONITORING, 2007, 29 (04) : 477 - 477
  • [24] Multicenter study of oxcarbazepine pharmacokinetics and tolerability in children with refractory epilepsy
    Dulac, O
    D'Souza, J
    Motte, J
    ANNALS OF NEUROLOGY, 2001, 50 (03) : S104 - S104
  • [25] Pharmacokinetic drug interactions in children taking oxcarbazepine
    Sallas, WM
    Milosavljev, S
    D'Souza, J
    Hossain, M
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 74 (02) : 138 - 149
  • [26] Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens
    Lin, Wei-wei
    Li, Xi-wen
    Jiao, Zheng
    Zhang, Jin
    Rao, Xin
    Zeng, Da-yong
    Lin, Xin-hua
    Wang, Chang-lian
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 75 (03) : 381 - 392
  • [27] Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric patients with epilepsy: Model-based dose optimization
    Wu, Wei
    Yang, Wen-sheng
    Xu, Xiao-yong
    Ge, Xi-lin
    Lu, Jinmiao
    Wang, Guang-fei
    Wang, Yi
    Li, Zhi-ping
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2024, 134 (05) : 712 - 726
  • [28] Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens
    Wei-wei Lin
    Xi-wen Li
    Zheng Jiao
    Jin Zhang
    Xin Rao
    Da-yong Zeng
    Xin-hua Lin
    Chang-lian Wang
    European Journal of Clinical Pharmacology, 2019, 75 : 381 - 392
  • [29] Drug Interaction and Pharmacokinetic Modeling of Oxcarbazepine in Korean Patients With Epilepsy
    Park, Kyoung-Jin
    Kim, Jung-Ryul
    Joo, Eun Yeon
    Seo, Dae Won
    Hong, Seung Bong
    Ko, Jae-Wook
    Kim, Suk-Ran
    Huh, Wooseong
    Lee, Soo-Youn
    CLINICAL NEUROPHARMACOLOGY, 2012, 35 (01) : 40 - 44
  • [30] Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children
    Rodrigues, Christelle
    Chiron, Catherine
    Rey, Elisabeth
    Dulac, Olivier
    Comets, Emmanuelle
    Pons, Gerard
    Jullien, Vincent
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 83 (12) : 2695 - 2708